Antares Pharma Inc (ATRS.OQ)
ATRS.OQ on NASDAQ Stock Exchange Capital Market
Change (% chg)
Revenue & Earnings Per Share
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
No consensus analysis data available.
|1 Year||3 Year||5 Year|
|EPS (TTM) %||-28.09||--||--|
Note: Units in Millions of US Dollars
Performance for Antares Pharma Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Antares Pharma Provides Xyosted Regulatory Update
- BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted
- BRIEF-Antares Pharma Q3 loss per share $0.03
- BRIEF-Antares Pharma receives complete response letter from FDA for Xyosted
- BRIEF-Antares Pharma says received FDA letter regarding deficiencies of its drug Xyosted
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.